Viemed Healthcare, Inc. (NASDAQ:VMD) Short Interest Down 19.4% in November

Viemed Healthcare, Inc. (NASDAQ:VMD) was the target of a large decrease in short interest in November. As of November 15th, there was short interest totalling 291,200 shares, a decrease of 19.4% from the October 31st total of 361,200 shares. Currently, 0.9% of the company’s stock are short sold. Based on an average daily volume of 166,700 shares, the days-to-cover ratio is presently 1.7 days.

Viemed Healthcare Trading Up 1.3 %

Shares of NASDAQ:VMD opened at $8.67 on Monday. The company’s 50-day moving average price is $8.61 and its two-hundred day moving average price is $7.62. Viemed Healthcare has a one year low of $6.21 and a one year high of $10.44. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.31 and a quick ratio of 1.19. The stock has a market capitalization of $337.58 million, a PE ratio of 32.11 and a beta of 1.43.

Viemed Healthcare (NASDAQ:VMD) last released its earnings results on Wednesday, November 6th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.02. The business had revenue of $58.00 million for the quarter. Viemed Healthcare had a return on equity of 8.72% and a net margin of 4.87%.

Insider Buying and Selling

In other news, Director Randy E. Dobbs sold 36,261 shares of Viemed Healthcare stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $9.28, for a total value of $336,502.08. Following the sale, the director now directly owns 107,706 shares in the company, valued at $999,511.68. This trade represents a 25.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nitin Kaushal sold 5,995 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $8.58, for a total transaction of $51,437.10. Following the transaction, the director now owns 126,843 shares of the company’s stock, valued at $1,088,312.94. The trade was a 4.51 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 72,256 shares of company stock valued at $674,739. 20.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Viemed Healthcare

A number of institutional investors have recently added to or reduced their stakes in the company. Barclays PLC increased its position in Viemed Healthcare by 342.3% during the third quarter. Barclays PLC now owns 53,439 shares of the company’s stock worth $392,000 after buying an additional 41,358 shares during the last quarter. National Bank of Canada FI boosted its stake in shares of Viemed Healthcare by 91.2% during the 3rd quarter. National Bank of Canada FI now owns 3,346 shares of the company’s stock worth $25,000 after acquiring an additional 1,596 shares during the period. Wasatch Advisors LP increased its holdings in shares of Viemed Healthcare by 19.6% during the 3rd quarter. Wasatch Advisors LP now owns 1,848,884 shares of the company’s stock worth $13,552,000 after acquiring an additional 303,277 shares during the last quarter. Raffles Associates LP raised its stake in Viemed Healthcare by 11.0% in the 3rd quarter. Raffles Associates LP now owns 402,691 shares of the company’s stock valued at $2,952,000 after acquiring an additional 40,000 shares during the period. Finally, PDT Partners LLC acquired a new stake in Viemed Healthcare during the 3rd quarter valued at $78,000. 74.24% of the stock is currently owned by institutional investors and hedge funds.

Viemed Healthcare Company Profile

Viemed Healthcare, Inc, together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.